Disappearance of circumscribed choroidal hemangiomas with photodynamic therapy

Pinheiro-Costa, João; Freitas-Costa, Paulo; Bragança, Teresa; Falcão‐Reis, Fernando; Carneiro, Ângela

doi:10.1016/j.pdpdt.2015.02.003

Cited by 1 publication

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with several previous studies [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ], the results of our case series confirm that symptomatic CCHs respond generally well to PDT, because 50% of patients exhibited a significant visual improvement. In particular, we identified young age (<50 years) and a pre-PDT BCVA ≥ 20/200 as pretreatment variables significantly associated with an improved post-treatment visual acuity.…”

Section: Discussionsupporting

confidence: 92%

“…In addition, exudative retinal detachment showing complete resolution within 1 month after PDT and a reduced post-PDT tumor thickness were identified as post-treatment variables associated with an improved BCVA. Although PDT is currently considered as the treatment of choice for symptomatic submacular and peripapillary CCHs [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ], some patients cannot afford its high cost. In this context, the selection of ideal candidates who are most likely to benefit from this approach is necessary.…”

Section: Discussionmentioning

confidence: 99%

“…The potential correlation between symptom duration before PDT and visual outcomes remains controversial. Some authors have suggested that longer symptom duration may be associated with a poor final visual acuity (≤ 20/200) [ 1 , 2 ], whereas other reports have not [ 8 , 9 , 10 , 11 , 12 ]. In our study, binary logistic regression analysis did not identify symptom duration as a significant predictor of visual outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…All patients underwent standard PDT (wavelength: 689 nm; light dose: 50 J/cm 2 ; exposure time: 83 sec per spot. The Coherent Lumenis Opal PDT laser, Lumenis, Inc, Santa Clara, California, USA), with verteporfin (6 mg/m 2 body surface; Visudyne, Norvatis Ophthalmics, Hettlingen, Switzerland) was used for treatment[ 8 , 9 , 10 , 11 , 12 , 18 ]. Multiple minimal overlapping spots were used to treat large CCHs.…”

Section: Methodsmentioning

confidence: 99%

“…Moreover, post-radiotherapy radiation retinopathy is a significant concern [ 2 , 4 , 5 ]. Owing to a low likelihood of treatment-related visual loss [ 6 , 7 , 8 , 9 , 10 , 11 , 12 ], photodynamic therapy (PDT) with verteporfin is currently considered as the first-line treatment modality for patients with CCHs with macular involvement [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Clinical outcomes and predictors of response to photodynamic therapy in symptomatic circumscribed choroidal hemangioma: A retrospective case series

Chao

Chen

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

BackgroundTo investigate the treatment outcomes and predictors of response to photodynamic therapy (PDT) in patients with symptomatic circumscribed hemangioma (CCH).MethodsThis retrospective case series examined 20 patients with symptomatic CCH (10 submacular CCHs and10 juxtapapillary CCHs) who underwent standard PDT (wavelength: 662 nm; light dose: 50J/cm2; exposure time: 83 sec) with verteporfin (6mg/m2), either as monotherapy (n = 9) or in association with other treatments (n = 11), of which 7 received intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF). A post-PDT improvement of at least two lines in best-corrected visual acuity (BCVA) was the primary outcome measure. Predictors of response were investigated with binary logistic regression analysis.ResultsSeventeen (85%) patients received one PDT session, and three patients (15%) underwent PDT at least twice. Ten patients (50%) achieved the primary outcome of a post-PDT BCVA improvement of at least two lines. Macular atrophy and recalcitrant cystoid macular edema in 2 patients. Binary logistic regression analysis revealed that younger age (< 50 years) (P = 0.033), pre-PDT BCVA of ≧20/200 (P = 0.013), exudative retinal detachment resolved within one month after PDT (P = 0.007), and a thinner post-PDT tumor thickness (P = 0.015) were associated with the achievement of a post-PDT BCVA improvement. Additional treatments to PDT including IVI anti-VEGF did not appear to improve visual and anatomical outcomes.ConclusionsSymptomatic CCHs respond generally well to PDT. Patients with younger age (< 50 years), pretreatment BCVA≥ 20/200, and thinner foveal edema are most likely to benefit from this approach.

show abstract